Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
r-phenylephrine is the dextrorotatory enantiomer of phenylephrine, a **small-molecule sympathomimetic alpha-1 adrenergic receptor agonist** used clinically as a vasoconstrictor and decongestant. The provided sources specifically discuss r-phenylephrine as the desired chiral product of biocatalytic synthesis from 1-(3-hydroxyphenyl)-2-(methylamino) ethanone using engineered or recombinant *Serratia marcescens* short-chain dehydrogenase/reductase systems, rather than as a novel proprietary development program. Pharmacologically, the active therapeutic effect is mediated primarily through stimulation of alpha-1 adrenergic receptors on vascular smooth muscle, producing vasoconstriction; this underlies uses such as nasal decongestion and hemodynamic support depending on formulation and route. The drug is an established pharmaceutical ingredient rather than a combination product, device, supplement, or biologic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on r-phenylephrine.